Novo Nordisk Shifts $600 Million U.S. Media Account to Omnicom

Novo Nordisk Hands Omnicom its U.S. Media Mandate

Novo Nordisk has appointed Omnicom as its U.S. media agency of record, following a competitive review that ends a six-year run with WPP’s Wavemaker. The pharmaceutical giant confirmed the change will take effect in the fourth quarter of 2026, handing Omnicom an account estimated to be worth at least $600 million in annual media spend, according to agency research firm COMvergence. The win is one of the largest media remits in the healthcare sector and signals Novo Nordisk’s intention to dramatically scale its direct-to-consumer presence.

In a statement, the company said it looked forward to working with the Omnicom team “as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes.” The language leaves little doubt that Novo Nordisk is moving beyond traditional physician-focused promotion and treating its blockbuster GLP-1 drugs—Wegovy and Ozempic—more like consumer health brands.

The backdrop is one of heated market rivalry. Last month Novo Nordisk sued Eli Lilly over what it calls false advertising for Lilly’s competing GLP-1 drug Zepbound. The two companies are locked in a fierce battle for dominance in the fast-growing weight-loss category, where patient loyalty and brand perception can shift rapidly. Against that landscape, the selection of a new media partner is not just a procurement decision—it is a strategic weapon.

Novo Nordisk’s Consumer Push, Omnicom’s Coup, and the GLP-1 Stakes

Novo Nordisk’s Consumer-Centric Shift

By explicitly spotlighting “consumer-focused strategies” and “emerging channels,” the company is signaling a clear pivot. Traditional pharma marketing has relied heavily on sales reps and medical journal advertising; the obesity market, however, has seen explosive growth of televised and digital direct-to-consumer ads. Novo Nordisk wants a media partner that can blend broadcast scale with the data-driven precision of digital platforms. Omnicom’s integrated offering, which spans performance marketing, data analytics, and creative, likely matched that brief better than Wavemaker’s more traditional approach.

Omnicom’s Win: A Coup with Broad Implications

For Omnicom, the account is a major addition to its health practice. The holding company’s Omnicom Health Group will now lead one of the largest media accounts in the agency world, providing a strong revenue stream and a prestige credential that could trigger a domino effect in pharmaceutical reviews. Winning Novo Nordisk demonstrates that Omnicom can handle the scale and complexity of a heavily regulated yet rapidly evolving consumer health category—a signal that may resonate with other large pharma advertisers weighing agency changes.

WPP Feels the Sting of a Key Client Exit

Losing a $600 million client is a significant blow to WPP, even for a holding company of its size. Wavemaker had held the U.S. duties since 2020, and the exit raises questions about whether WPP retains any other Novo Nordisk work—such as creative, digital, or international media assignments. If the breakup is total, WPP’s healthcare agency network may need to re-pitch aggressively for competing GLP-1 business or look to other health categories to fill the gap. The news also heightens attention on WPP’s ability to defend large-scale accounts as marketers increasingly seek integrated, data-rich solutions.

The Lilly Factor: Media as a Battlefield

The timing of the review, coming just weeks after Novo Nordisk’s lawsuit against Eli Lilly, is unlikely to be coincidental. With both companies vying for the same patient population, the effectiveness of consumer advertising could directly influence prescription share. Novo Nordisk’s move to a new agency suggests it is seeking fresh messaging and channel strategies to differentiate Wegovy from Zepbound. Meanwhile, Lilly can be expected to answer with its own ramped-up marketing push, raising the stakes—and the media budgets—in what is already one of the most competitive therapeutic categories in history.

Novo Nordisk, Omnicom, and WPP: The Road Ahead

For the businesses and investors connected to this shift, here are the concrete takeaways:

• Novo Nordisk’s leadership must deliver measurable consumer engagement. The switch to Omnicom is a bet on digital and emerging-channel effectiveness. Marketing teams should establish clear KPIs—brand awareness lift, search volume, and ultimately prescription intent—well ahead of the Q4 2026 launch, then track them rigorously to justify the investment.
• Omnicom’s immediate priority is faultless onboarding. Demonstrating rapid wins in reach and cost-efficiency will be critical to retaining a demanding new client and using the account as a proof point in future pharma pitches. The agency’s health group should assign a dedicated senior leadership layer to the account and ensure data and analytics integration is operational from day one.
• WPP must move quickly to contain the damage. Leadership at Wavemaker and the wider WPP health network should clarify whether any creative, digital, or international assignments with Novo Nordisk remain. Concurrently, they should pursue a pitch for Lilly’s media business or that of other GLP-1 makers—a category whose marketing outlays are only set to grow.
• Investors should note the revenue implications. Omnicom (NYSE: OMC) stands to add a high-margin media client that will lift its health revenue base, while WPP (LON: WPP) faces a composition headwind. The financial impact will be modest at the group level, but sentiment around agency holding companies can shift on account wins and losses of this size.
• Eli Lilly’s countermove is inevitable. Expect the rival to increase its own U.S. media spending, particularly in television and digital video, to defend Zepbound’s position. Media buying agencies with health specialization should brace for a surge in briefs as the GLP-1 advertising arms race intensifies.